INBJUDAN TILL TECKNING AV AKTIER INFÖR LISTNING PÅ

Svenska Webbtidningar - prepona.info

2020-09-21 Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of 2020-09-21 Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology. Immunicum AB is a biopharmaceutical company. It develops immune therapies against a range of solid tumors.

Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Sijme Zeilemaker, COO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. 2020-09-21 · E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

RENA RUM - Rentforum - Yumpu

2020-09-21 · E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal Immunicum is focused on demonstrating the therapeutic value of ilixadencel and DCP-001 through a broad clinical pipeline that supports a rapid path to commercialization and patient access. IMMUNICUM Aktiebolag,556629-1786 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för IMMUNICUM Aktiebolag Immunicum AB is a biopharmaceutical company. It develops immune therapies against a range of solid tumors.

Bra Aktie Att Köpa Nu - prepona.info

STOCKHOLM (Nyhetsbyrån Direkt) Immunicum har erhållit snabbspårsstatus, så kallad Fast Track Designation, från den amerikanska läkemedelsmyndigheten, FDA, för bolaget Immunicum. Immunicum befinner sig i en framskriden klinisk ut-vecklingsfas medan start up-bolaget Asgard Therapeutics är i preklinisk fas.

556629-1786|immunicum.se . MEDIA RELATIONS Gretchen Schweitzer and Joanne Tudorica . Trophic Communications .
Mina anger rektor

U.S. AND INTERNATIONAL INVESTO R RELATIONS Thomas Renaud . Arrowhead Business and Investment E-mail: ir@immunicum.com. Media Relations. Eva Mulder and Sophia Hergenhan, Ph.D. Trophic Communications Telephone: +49 175 222 57 56 E-mail: ir@immunicum.com.

Media Relations. Eva Mulder and Sophia Hergenhan, Ph.D. Trophic Communications Telephone: +49 175 222 57 56 E-mail: ir@immunicum.com. About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors.
Munters service stockholm

pergo golv kontakt
frukost mcdonalds örebro
omx nasdaq sverige
traditionellt påskbord
mat på vikingatiden unga fakta
bygglov ostersund

ProsPekt avseende uPPtagande till handel av - Cantargia

Immunicum AB is a biopharmaceutical company. It develops immune therapies against a range of solid tumors.

magnus_persson Magnus Persson SD - Riksdagen - Insta Stalker

Immunicum AB (publ)| Östermalmstorg 5, 114 42 Stockholm| Tel +46 87328 400| Orgnr. 556629-1786|immunicum.se . Press Release . 21 September 2020 . Immunicum AB: Invitation to Corporate Update Event Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020. 2021-04-12 · Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com.

Immunicum's business currently consists of research and development for production of pharmaceuticals. Experience: Erik Manting worked for a number of years in the field of immunology before making a career switch to banking in 2001.He spent the next 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co, an investment bank with a focus on Life Sciences & Healthcare. E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Sven Rohmann, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: [email protected] Sijme Zeilemaker, COO, Immunicum Telephone: +46 8 732 8400 E-mail: [email protected] About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. E-mail: ir@immunicum.com. Media Relations.